---
schema_version: "secwatch.filing_event.v1"
accession: "0001520138-22-000553"
form_type: "8-K"
ticker: "BIVI"
cik: "0001580149"
company_name: "BIOVIE INC."
filed_at: "2022-12-07T23:59:59+00:00"
generated_at: "2026-06-21T08:08:17.189443+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioVie reports positive NE3107 data in Parkinson's, Alzheimer's, and aging biomarkers

## Summary
- NE3107+levodopa improved UPDRS Part 3 by 3+ points vs levodopa alone at 2-3 hours (clinically meaningful); 6+ points for patients <70.
- NE3107 improved cognition: ADAS-Cog12 +2.2 points (p=0.0173), CDR +0.11 (p=0.0416), ADCOMS +0.07 (p=0.0094) in mild cognitive impairment/mild AD.
- NE3107 reduced Horvath DNA methylation SkinBlood clock by 3.3 years (p=0.0021) after 3 months; 19 of 22 patients showed reduction.
- BioVie increased Phase 3 AD trial enrollment from 316 to 400; topline results expected before end of Q3 2023.
- Company plans to discuss Phase 3 Parkinson's program with FDA and expects to launch Phase 3 trials in 2023.

## SEC filing metadata
- accession: 0001520138-22-000553
- form_type: 8-K
- ticker: BIVI
- cik: 0001580149
- company_name: BIOVIE INC.
- filed_at: 2022-12-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1580149/000152013822000553/0001520138-22-000553-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1580149/000152013822000553/bivi-20221207_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001520138-22-000553
- JSON: https://secwatch.observer/filing/0001520138-22-000553.json
- Plain text: https://secwatch.observer/filing/0001520138-22-000553.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.